| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/12/2005 | CN1184215C Substd. oxazoles and thiazoles derivs. as HPPAR alpha activators |
| 01/12/2005 | CN1184208C Substituted benzimidazoles and their prepn. and use |
| 01/12/2005 | CN1184204C Piperidine compounds for use as CCR-3 inhibitors |
| 01/12/2005 | CN1183948C Medicine for treating thrumatism and preparation method |
| 01/12/2005 | CN1183944C Medicament for curing vitro wetness cold illness |
| 01/12/2005 | CN1183916C Use of lactic acid bacterium for the treatment of peritonitis |
| 01/12/2005 | CN1183901C Pharmaceutical compositions capable of being gelled |
| 01/11/2005 | US6841698 Aminopropylphosphinic acids |
| 01/11/2005 | US6841674 N-heterocyclic derivatives as NOS inhibitors |
| 01/11/2005 | US6841673 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents |
| 01/11/2005 | US6841571 Compounds useful as reversible inhibitors of cysteine proteases |
| 01/11/2005 | US6841567 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/11/2005 | US6841564 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/11/2005 | US6841550 Benzoxazine and benzothiazine derivatives and their use in medicines |
| 01/11/2005 | CA2342072C Kunitz domain polypeptide zkun6 |
| 01/11/2005 | CA2069870E Treatment of atopic disorders with gamma-interferon |
| 01/06/2005 | WO2005001732A1 Medical care self-cell delivery support system, medical care self-cell delivery support financial system, and their methods |
| 01/06/2005 | WO2005000831A1 ESTERS OF FLAVONOIDS WITH ω-SUBSTITUTED C6-C22 FATTY ACIDS |
| 01/06/2005 | WO2005000820A2 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists |
| 01/06/2005 | WO2005000817A2 Diphenylpyridine derivatives, preparation and therapeutic application thereof |
| 01/06/2005 | WO2005000406A2 Treatment of amyloid- and epileptogenesis-associated diseases |
| 01/06/2005 | WO2005000344A2 Method for identification of tr1 lymphocytes regulators by the presence and overexpression of specific molecules and application thereof |
| 01/06/2005 | WO2005000310A1 Multiparticulates |
| 01/06/2005 | WO2005000298A2 5-membered heterocycle-based p-38 inhibitors |
| 01/06/2005 | WO2005000290A1 Ibuprofen-containing film-coated tablet |
| 01/06/2005 | WO2005000287A1 External preparation for athlete's foot treatment |
| 01/06/2005 | WO2004089417A9 Drug-enclosing multilayer structure particulate and process for producing the same |
| 01/06/2005 | WO2004087646A3 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 01/06/2005 | WO2004082574A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d5 (drd5) |
| 01/06/2005 | WO2004073586A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor tg1019 (tg1019) |
| 01/06/2005 | WO2004071392A3 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) |
| 01/06/2005 | WO2004071378A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 01/06/2005 | WO2004042342A3 Nuclear pore protein nup88 as a novel target |
| 01/06/2005 | WO2003042177A8 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 01/06/2005 | WO2003032907A9 High-concentration protein formulations and method of manufacture |
| 01/06/2005 | US20050004204 2-Iminopyrrolidine derivatives |
| 01/06/2005 | US20050004202 Such as 3-[1-(3-methoxypropyl )-1H-indazol-3-yl]-4-[1-(3-pyridinyl )-1H-indol-3-yl]-1H-pyrrole-2,5-dione; protein kinase C and/or glycogen synthase kinase-3 diseases |
| 01/06/2005 | US20050004199 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 01/06/2005 | US20050004197 Thrombin receptors antagonists; oral efficacy |
| 01/06/2005 | US20050004195 Inhibitors of phosphoinositide 3 kinases; inflammatory diseases, cardiovascular disorders, cancers; such as 5,6-dimethoxy-3-o-tolylsulfanyl-1H-indole-2-carboxylic acid-(2H-tetrazol-5-yl)-amide |
| 01/06/2005 | US20050004191 Crystallization production of form II; yield, low cost; does not requires rapid cooling |
| 01/06/2005 | US20050004186 Phenyl-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine derivatives; immunomodulators; inflammation, proliferative diseases |
| 01/06/2005 | US20050004180 Conditions mediated by beta chemokine receptor 2, monocyte chemotactic protein 1 and/or their interaction; such as 4-acetyl-5-cyclohexyl-3-amino-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one |
| 01/06/2005 | US20050004164 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| 01/06/2005 | US20050004153 inhibitors of Lymphocyte Function-associated Antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM); use treating transplant rejection, rheumatoid arthritis, diabetes, inflammatory bowel disease, and chronic obstructive pulmonary disease; 2,4-dioxo-1,3,7-triazaspiro[4.4]nonanes |
| 01/06/2005 | US20050004150 For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders |
| 01/06/2005 | US20050004142 furo(2,3-d)pyrimidine and thieno(2,3-d)pyrimidine compounds for treating cancer and hyperproliferative diseases; receptor tyrosine kinase inhibitors |
| 01/06/2005 | US20050004140 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states |
| 01/06/2005 | US20050004136 Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful as neurokinin receptor modulators |
| 01/06/2005 | US20050004135 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 01/06/2005 | US20050004134 Adenosine antagonists; having 6-oxo-1,6-dihydro-3-pynidazinyl functionality; synthesis |
| 01/06/2005 | US20050004133 Inhibiting ligand gated ion channel vanilloid receptor (VR1); pain relievers; such as 6-(3,4-dichloro-phenyl)-N-(2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-nicotinamide |
| 01/06/2005 | US20050004132 Pain, immune diseases, inflammatory disorders; low toxicity; such as 1-[2-(3-(4-Pyridyl)phenyl)ethyl]-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 1-oxide |
| 01/06/2005 | US20050004126 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors |
| 01/06/2005 | US20050004125 Such as 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; bipolar disorder, pain, type 2 diabetes |
| 01/06/2005 | US20050004124 Synergistic mixture; antidiabetic agents; antiischemic agents |
| 01/06/2005 | US20050004119 Trypsin like serine protease enzyme inhibitors |
| 01/06/2005 | US20050004118 Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds |
| 01/06/2005 | US20050004116 Triazole inhibitors of type 2 methionine aminopeptidase |
| 01/06/2005 | US20050004110 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 01/06/2005 | US20050004096 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 01/06/2005 | US20050004082 Ether compounds |
| 01/06/2005 | US20050004073 Pharmaceutical composition comprising chito-oligomers |
| 01/06/2005 | US20050004068 Modulation of tor |
| 01/06/2005 | US20050004035 Antiinflammatory agents; multiple sclerosis; inflamamtory bowel disorders; antitumor agents; sepsis |
| 01/06/2005 | US20050003473 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase |
| 01/06/2005 | US20050003457 Immunoglobulin which binds osteoclastogenesis inhibitory factor binding molecules (OBM)) and prevents bone resorption for use in treatment and prevention of bone disorders |
| 01/06/2005 | US20050003451 Immunoglobulin for use in diagnosis, prevention and treatment of infection, autoimmune, inflammatory and cell proliferative diseases; immunotherapy |
| 01/06/2005 | US20050003446 Peptide sequences for use in identification of modulators for use in treatment and prevention of inflammatory, cell proliferative, arteriosclerotic and skin disorders |
| 01/06/2005 | US20050003391 Bioassay for detection of receptor activated nuclear factor kappa beta ligand (RANKL); identifying modulator immune and inflammatory response |
| 01/06/2005 | US20050003370 Expression vector comprising nucleotide sequences coding membrane receptor proteins for use in identifying modulators for treatment and prevention of cell proliferative, nervous system, reproductive cardiovascular and inflammation disorders |
| 01/06/2005 | US20050003014 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| 01/06/2005 | US20050003002 Tramadol hydrochloride with such as diclofenac sodium; reduced water solubility |
| 01/06/2005 | US20050003000 Method for the the formation of ibuprofen crystals |
| 01/06/2005 | US20050002986 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/06/2005 | US20050002961 Concentrate comprising green tea, grape skin extract and grape extract, the production thereof and use of the same |
| 01/06/2005 | US20050002936 Methods and compositions useful for inhibition of angiogenesis |
| 01/06/2005 | US20050002932 Alleviation of symptoms associated with inflammatory disease states |
| 01/06/2005 | CA2556706A1 Treatment of amyloid- and epileptogenesis-associated diseases |
| 01/06/2005 | CA2530385A1 Melt extruded controlled release oxycodone multiparticulates |
| 01/06/2005 | CA2529941A1 Method for identification of tr1 lymphocytes regulators by the presence and overexpression of specific molecules and application thereof |
| 01/06/2005 | CA2528619A1 Diphenylpyridine derivatives, preparation and therapeutic application thereof |
| 01/06/2005 | CA2528438A1 P-38 inhibitors |
| 01/06/2005 | CA2526971A1 Novel dermatological composition |
| 01/05/2005 | EP1493810A1 DNA-based aptamers for human cathepsin G |
| 01/05/2005 | EP1493745A1 New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound |
| 01/05/2005 | EP1493743A1 Substituted bipiperidine intermediates and derivatives thereof |
| 01/05/2005 | EP1493735A1 Pyrimidine derivatives useful as selective cox-2 inhibitors |
| 01/05/2005 | EP1493732A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 01/05/2005 | EP1493442A1 Reboxetine for treating peripheral neuropathy |
| 01/05/2005 | EP1493431A2 Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions |
| 01/05/2005 | EP1493034A2 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 01/05/2005 | EP1492868A2 Method of modulating inflammatory response |
| 01/05/2005 | EP1492817A2 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 01/05/2005 | EP1492811A1 Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin |
| 01/05/2005 | EP1492803A1 New analogs of nitrobenzylthioinosine |
| 01/05/2005 | EP1492797A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof |
| 01/05/2005 | EP1492795A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 01/05/2005 | EP1492793A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives |
| 01/05/2005 | EP1492792A2 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |